Update on CheckMate 067, an advanced melanoma clinical trial - European Medical Journal

Update on CheckMate 067, an advanced melanoma clinical trial

Oncology

James Larkin, MD, PhD gives an update on the clinical trial CheckMate 067, a phase 3 study of Nivolumab or Nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma.

This updated was presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>